NCT05653882
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05653882
Title A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Asher Biotherapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
UCLA Los Angeles California 90095 United States Details
UCSD San Diego California 92037 United States Details
UCSF San Francisco California 94143 United States Details
Yale New Haven Connecticut 06510 United States Details
University of Miami Miami Florida 33136 United States Details
Ocala Oncology Center Ocala Florida 34474 United States Details
University of Chicago Medical Center Chicago Illinois 60637 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Washington University St Louis Missouri 63110 United States Details
Rutgers New Brunswick New Jersey 08901 United States Details
NYU New York New York 10016 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
Providence Cancer Institute Franz Clinic Portland Oregon 97213 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Intermountain Health Murray Utah 84107 United States Details
Virginia Commonwealth Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field